We have previously shown that patients at high risk of graft-versus-host disease (GVHD) and transplantrelated mortality (TRM) can be identified on day +7 following an allogeneic bone marrow transplant (BMT), based on serum bilirubin and blood urea nitrogen levels. One possible approach to reduce the risk of GVHD and TRM, is pre-emptive treatment with T cell antibodies. We report a pilot study testing the feasibility of this approach in 18 high risk patients, with a median age of 41, 83% of whom had advanced disease, undergoing an alternative donor BMT (family mismatched in five and unrelated in 13). The patients received three doses of rabbit antithymocyte globulin (ATG) (Thymoglobuline; Sangstat) 1.25 mg/kg on alternate days, starting at a median interval of 11 days (range 7-13) after BMT. Controls were 20 historical unrelated donor transplants (median age 35, 63% with advanced disease), with a high score from our original publication in 1999. The actuarial 1 year TRM of the ATG-treated patients was 40% compared to 60% for untreated controls (P = 0.06). Severe grade III-IV aGVHD developed in 27% of the ATG-treated patients, and in 55% of the controls (P = 0.08). This study indicates that early preemptive treatment of aGVHD in day +7 high risk patients is feasible and may lead to a reduction of aGVHD and TRM. This approach is being tested in a prospective randomized trial. Bone Marrow Transplantation (2001) 28, 1093-1096. Keywords: bone marrow transplantation; anti-thymocyte globulin; graft-versus-host disease Graft-versus-host disease (GVHD) remains a significant problem in patients receiving a bone marrow transplant (BMT), especially if the transplant is from an alternative donor.
grade III-IV disease. 3 Early identification of patients at risk may therefore be clinically useful. In a previous study we have described a scoring system based on blood urea nitrogen (BUN) and serum bilirubin levels on day +7 after allogeneic BMT. 4 Patients with bilirubin levels of у0.9 mg/dl and BUN у21 mg/dl had a transplant-related mortality (TRM) of 44%, compared to 22% for patients with scores 0-1 (either bilirubin Ͻ0.9 mg/dl or BUN Ͻ21 mg/dl). High risk patients had significantly more grade III-IV acute GVHD (19% vs 11%, P = 0.03) and significantly lower platelet counts. 4 This suggests the possibility of identifying patients at high risk of transplant-related complications, including acute GVHD early after BMT. If this is the case, it should then be possible to pre-emptively treat patients at risk of GVHD and TRM with T cell antibodies. This has already been proven some years ago in a randomized trial published by Ramsay and coworkers:
5 patients receiving seven doses of anti-thymocyte globulin (ATG), starting on day +8 after BMT, had significantly less GVHD as compared to controls.
With these two premises in mind we opened a pilot study of low-dose alternate day ATG as pre-emptive treatment of GVHD for day +7 high risk patients, and we report here 18 patients, together with 20 untreated controls. All patients were recipients of an alternative donor transplant.
Materials and methods

Day +7 score
The scoring system has been previously described. 4 All patients in this study had serum bilirubin levels of у0.9 mg/dl and BUN levels of у21 mg/dl on day +7 after BMT.
Transplant procedures
Patients were cared for in single rooms with HEPA-filtered air from day −7 until at least day +30, when they were discharged either to a conventional care unit, or to the outpatient clinic. Clinical details are outlined in Table 1 . All patients received high-dose immunoglobulins (HDIgG) 400 mg/kg/week from day −7 untill day +100. 
HLA matching
Donors were either one antigen family mismatched with the recipient or matched unrelated (UD) selected by the Italian Bone Marrow Donor Registry (IBMDR). In the latter case donors were matched by serology for class I antigens, including split antigens, and by molecular biology for class II, including high resolution sequence-based typing (SBT) for DRB1 and sequence-specific oligotyping (SSO) for DRB3, DRB4.
Conditioning regimen
Conditioning consisted of either thiotepa 15 mg/kg, rabbit antithymocyte globulin (ATG) (Thymoglobuline, Sangstat, Lyon, France) 15 mg/kg and cyclophosphamide (CY) 150 mg/kg, 6 or CY 120 mg/kg and total body irradiation (TBI) 9 Gy in three fractions or 12 Gy in six fractions. 7 The source of stem cells was bone marrow for all patients.
GVHD prophylaxis
All patients received cyclosporin A (CsA) 1 mg/kg as a continuous i.v. infusion from day −7 to day −1, then 2 mg/kg i.v. from day 0 to day +20 and then 5-10 mg/kg/day p.o. from day +21 until at least day +365. Methotrexate (MTX) was given at the conventional dose of 15 mg/m 2 on day +1, and 10 mg/m 2 days +3, +6 and +11.
CMV prophylaxis
All patients received foscarnet from day −7 to day +30 at the dose of 30 mg/kg twice daily, then 90 mg/kg/day 5 days/week from day +31 to day +100. Patients were monitored once a week from day +1 to day +30 then twice weekly until day +100 for CMV antigenemia, as described elsewhere. CMV antigenemia was treated by adding ganciclovir (5-10 mg/kg/day for 15 days) to the prophylactic foscarnet.
Antithymocyte globulin (ATG) treatment
Rabbit ATG (Thymoglobuline; Sangstat, Lyon, France) was given at a dose of 1.25 mg/kg on alternate days for three doses (total dose administered 3.75 mg/kg). One patient received five doses (total dose 7.5 mg/kg). All patients were pre-medicated with steroids and anti-histamine, and ATG was always given as a slow intravenous drip lasting at least 4 h. With this pre-medication there were no significant allergic reactions.
Statistical methods
Comparisons of proportions were based on the chi-square test or Fisher's exact test, as appropriate. Differences between continuous variables were tested by the MannWhitney test. Survival curves in each study group were computed by the Kaplan-Meier method, 8 and compared by means of the standard log-rank procedures. All tests were two-sided.
Results
Tolerance of ATG and engraftment
At the time of ATG treatment all patients were pancytopenic: the median day of first administration was day 11 (range 7-13). Treatment was well tolerated. All patients achieved a neutrophil count of 0.5 × 10 9 /l with a median interval from transplant of 11 (7-22) days, which did not differ from controls ( Table 2 ). The median platelet count on day +50 after BMT was 98 × 10 9 /l (range 13-330), and 52 (range 11-116) in controls.
Acute graft-versus-host disease (GVHD)
Acute GVHD was scored as grades 0-I, II, III-IV in two, 11 and five patients treated with ATG, compared to four, five and 11 in the control arm. Severe (grade III-IV) GVHD was therefore 28% in the ATG group compared to 55% in the control group (P = 0.08 by Fisher's exact test).
Causes of death
In the ATG arm causes of death were acute GVHD (n = 2), infections (n = 6), graft failure (n = 1) and leukemia (n = 1). In the control arm causes of death were GVHD (n = 7), infections (n = 5) and graft failure (n = 1) ( Table 2) . The difference in death due to GVHD (11% vs 35%) is of borderline significance.
Transplant-related mortality
The actuarial 1 year TRM of the ATG-treated patients was 40% compared to 60% for untreated controls (P = 0.06) 1095 Table 2 Outcome of patients in the two arms ( Figure 1 ). The overal actuarial 1 year survival is 43% vs
Discussion
This is a pilot study, designed to test the feasibility of preemptive treatment of GVHD in patients receiving an alternative donor transplant, identified to be at high risk on day +7 after BMT. We have shown that low-dose rabbit ATG is well tolerated, does not delay engraftment and may reduce the risk of severe acute GVHD as compared to untreated controls grafted from an alternative donor. This is in keeping with a previous trial, published some years ago, showing that early administration of ATG after an 
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HLA-identical sibling transplant, could significantly reduce the risk of acute GVHD. 5 However, in that study all patients were randomized to receive or not to receive ATG, whereas in the present study we selected patients identified to be at risk of acute GVHD and TRM on the basis of laboratory tests, namely bilirubin and blood urea nitrogen (BUN) and we also used a different brand of ATG. Despite the selection of these high risk patients, pre-emptive lowdose Thymoglobulin seemed to reduce GVHD and TRM.
ATG is widely used in many centers for the management of acute GVHD, usually as second-line therapy for patients not responding to first-line steroids. [9] [10] [11] The benefit of ATG in this setting is uncertain, and a recent randomized trial would have disproved the advantage of adding ATG to conventional steroids. 12 It should be noted that in a separate randomized study, intensified treatment with high-dose prednisolone proved equally ineffective in preventing progression of GVHD to grade III-IV in 17-20% of patients. 3 Therefore, it would seem that the intensity of immunosuppressive treatment is of little effect once GVHD is fully established. This may be related to the nature of the disease, largely due to toxic cytokines released by activated donor T cells, but possibly also by autologous activated macrophages. 13 Treatment at this stage may be too late, because tissue damage has already taken place and cytokine production by autologous macrophages could proceed undisturbed: the question is, can established GVHD be reversed at all. Whatever the answer to that question, many investigators would agree that GVHD should be prevented rather than treated. As we have learned over the past decade from CMV infections, pre-emptive treatment is an effective way of preventing CMV disease.
14 With the availability of day +7 markers of GVHD, pre-emptive treatment with low-dose ATG may be one possibility.
The small group of patients of this pilot study tolerated treatment well and showed hematologic recovery compara-ble to controls. The risk of developing grade III-IV acute GVHD was reduced without a corresponding increase in the risk of lethal infections. Transplant mortality was also reduced with borderline statistical significance: the fact that the ATG-treated group contained a greater number of patients conditioned without TBI, should not be regarded as a relevant bias. In a recent study, we showed that the thiotepa regimen for alternative donor transplants has a mortality comparable to that of the TBI regimen in matched patients. 6 This is not a prospective randomized trial and control patients, although matched for donor type and risk score on day +7, were treated in a different time period, before this study. We also do not know whether early treatment with ATG may increase the risk of leukemia relapse. A prospective randomized trial is needed to prove whether pre-emptive ATG treatment on day +7 after BMT will reduce the incidence of severe acute GVHD and of transplant-related mortality in high risk patients. This trial has now been activated.
